Xinri Hengli (600165) review: Transboundary stem cells enter the biotechnology medical industry
[Zhongshan Securities] Xinri Hengli: the acquisition of high-quality assets improves the profit structure, and the original business bottleneck still needs to be broken.
[Tianxiang Investment] Ningxia Hengli: the expense rate is high during the period, and the annual loss is more likely.
No Data